GlaxoSmithKline, Innoviva Asthma Inhaler Meets Primary Endpoint in Trial

Date : 05/02/2019 @ 5:59PM
Source : Dow Jones News
Stock : Glaxosmithkline (GSK)
Quote : 40.96  -0.45 (-1.09%) @ 12:59AM

GlaxoSmithKline, Innoviva Asthma Inhaler Meets Primary Endpoint in Trial

Glaxosmithkline (LSE:GSK)
Historical Stock Chart

3 Months : From Apr 2019 to Jul 2019

Click Here for more Glaxosmithkline Charts.
   By Adria Calatayud 

GlaxoSmithKline PLC (GSK.LN) and Innoviva Inc. (INVA) said Thursday that their Trelegy Ellipta inhaler, which treats patients living with uncontrolled asthma, met the primary endpoint in a phase 3 study.

The pharmaceutical companies said the study showed a statistically significant improvement in lung function at 24 weeks of once-daily treatment with Trelegy Ellipta compared with other medication.

However, the drug didn't achieve a statistically significant reduction in the annualized rate of asthma exacerbations, which was the secondary endpoint of the trial, the companies said.


Write to Adria Calatayud at


(END) Dow Jones Newswires

May 02, 2019 12:44 ET (16:44 GMT)

Copyright (c) 2019 Dow Jones & Company, Inc.

Latest GSK Messages

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....

No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Your Recent History
Gulf Keyst..
FTSE 100
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

NYSE, AMEX, and ASX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.